De Marco L, Mashiter K, Caughey B, Peters T J
Endocrinology. 1984 Sep;115(3):984-9. doi: 10.1210/endo-115-3-984.
Effects of the dopamine agonist 2-bromo-alpha-ergocryptine (bromocriptine) on plasma and pituitary PRL and enzyme activities in lactating and postlactating rats have been investigated. Lactating rats which had been suckling their young for 3 days were given a single sc injection of bromocriptine or solvent. The treated and control animals were divided into 2 further groups. One group (lactating rats) was permitted to suckle their pups for a further 12 or 24 h; the young were removed from the other group (postlactating rats). Homogenates were prepared from the anterior pituitaries and assayed for organelle marker enzyme activities. When 0.5-500 micrograms bromocriptine were administered to lactating rats for 24 h, pituitary PRL was increased by all doses, but only the 500-micrograms dose significantly reduced plasma PRL. Total protein was unchanged, lysosomal acid PRL proteolytic activity increased 8-fold, N-acetyl-beta-glucosaminidase and beta-glucuronidase (lysosomes) were unchanged, acid phosphatase (lysosomes and endoplasmic reticulum) was increased by three of four doses, 5'-nucleotidase and alkaline phosphatase (plasma membrane) were increased 4-fold, neutral-alpha-glucosidase (endoplasmic reticulum) and malate dehydrogenase (mitochondria) were unchanged, and catalase (peroxisomes) was significantly increased. Bromocriptine (500 micrograms) administration to lactating and postlactating rats for 12 and 24 h significantly decreased the pituitary DNA but not the total protein content of the pituitaries in all animals. The lysosomal acid PRL proteolytic activity and the lysosomal enzyme activities, N-acetyl-beta-glucosaminidase and beta-glucuronidase, were increased by suckling withdrawal alone. Acid PRL proteolytic activity was further increased (to 18-fold) by coadministration of bromocriptine, whereas the increase in the activities of the other lysosomal marker enzymes was blocked. Malate dehydrogenase activity (mitochondria) was also increased by litter removal and blocked by bromocriptine. The activity of the plasma membrane markers 5'-nucleotidase and alkaline phosphatase were increased by litter removal, and bromocriptine further increased both enzyme activities. The activity of neutral-alpha-glucosidase (endoplasmic reticulum) was unchanged by any treatment. The results demonstrate that bromocriptine produces significant changes in the activities of lysosomal marker enzymes, particularly acid PRL proteolytic activity, as well as marker enzymes of plasma membranes and other organelles in pituitaries of lactating and postlactating rats.
已研究了多巴胺激动剂2-溴-α-麦角隐亭(溴隐亭)对泌乳期和泌乳后期大鼠血浆及垂体催乳素(PRL)和酶活性的影响。对已哺乳幼崽3天的泌乳期大鼠进行单次皮下注射溴隐亭或溶剂。将处理过的动物和对照动物进一步分为两组。一组(泌乳期大鼠)再允许其哺乳幼崽12或24小时;另一组(泌乳后期大鼠)的幼崽被拿走。从前垂体制备匀浆并测定细胞器标记酶活性。当给泌乳期大鼠注射0.5 - 500微克溴隐亭24小时时,所有剂量均使垂体PRL增加,但只有500微克剂量显著降低血浆PRL。总蛋白未改变,溶酶体酸性PRL蛋白水解活性增加8倍,N-乙酰-β-葡萄糖胺酶和β-葡萄糖醛酸酶(溶酶体)未改变,酸性磷酸酶(溶酶体和内质网)在四个剂量中有三个使活性增加,5'-核苷酸酶和碱性磷酸酶(质膜)活性增加4倍,中性-α-葡萄糖苷酶(内质网)和苹果酸脱氢酶(线粒体)未改变,而过氧化氢酶(过氧化物酶体)显著增加。给泌乳期和泌乳后期大鼠注射500微克溴隐亭12和24小时,显著降低所有动物垂体中的DNA,但不降低垂体的总蛋白含量。仅断奶就使溶酶体酸性PRL蛋白水解活性以及溶酶体酶活性、N-乙酰-β-葡萄糖胺酶和β-葡萄糖醛酸酶增加。联合使用溴隐亭使酸性PRL蛋白水解活性进一步增加(至18倍),而其他溶酶体标记酶活性的增加被阻断。拿走幼崽也使苹果酸脱氢酶活性(线粒体)增加,并被溴隐亭阻断。质膜标记物5'-核苷酸酶和碱性磷酸酶的活性因拿走幼崽而增加,溴隐亭进一步增加这两种酶的活性。中性-α-葡萄糖苷酶(内质网)的活性不受任何处理的影响。结果表明,溴隐亭使泌乳期和泌乳后期大鼠垂体中溶酶体标记酶的活性发生显著变化,特别是酸性PRL蛋白水解活性,以及质膜和其他细胞器的标记酶活性。